Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different K-RAS Status

Yu-Tang Chin 1,2†, Zong-Rong He 3,4†, Chi-Long Chen 5,6, Hsiao-Ching Chu 6, Yih Ho 1,7, Po-Yu Su 8, Yu-Chen S. H. Yang 9, Kuan Wang 5,6, Ya-Jung Shih 1,8, Yi-Ru Chen 1,8, Jens Z. Pedersen 10, Sandra Incerpi 11, André Wendindondé Nana 12, Heng-Yuan Tang 13, Hung-Yun Lin 1,12,13,14,15*, Shaker A. Mousa 13, Paul J. Davis 13,16 and Jacqueline Whang-Peng 1,2,12‡

Colorectal cancer is a serious medical problem in Taiwan. New, effective therapeutic approaches are needed. The selection of promising anticancer drugs and the transition from pre-clinical investigations to clinical trials are often challenging. The deaminated thyroid hormone analog (tetraiodothyroacetic acid, tetrac) and its nanoparticulate analog (NDAT) have been shown to have anti-proliferative activity in vitro and in xenograft model of different neoplasms, including colorectal cancers. However, mechanisms involved in tetrac- and NDAT-induced anti-proliferation in colorectal cancers are incompletely understood. We have investigated possible mechanisms of tetrac and NDAT action in colorectal cancer cells, using a perfusion bellows cell culture system that allows efficient, large-scale screening for mechanisms of drug actions on tumor cells. Although integrin αvβ3 in K-RAS wild type colorectal cancer HT-29 cells was far less than that in K-RAS mutant HCT116 cells, HT-29 was more sensitive to both tetrac and NDAT. Results also indicate that both tetrac and NDAT bind to tumor cell surface integrin αvβ3, and the agents may have different mechanisms of anti-proliferation in colorectal cancer cells. K-RAS status appears to play an important role in drug resistance that may be encountered in treatment with this drug combination.

Keywords: perfusion bellows cell culture system, colorectal cancer cells, anticancer, phosphoERK1/2, NDAT, tetrac, integrin αvβ3
INTRODUCTION

The well-demonstrated receptor of thyroid hormone on the extracellular domain of plasma membrane integrin αβ3 is mainly expressed on tumor cells and dividing blood vessel cells. Steroid hormones (1–3) and thyroid hormones (L-thyroxine, T4, and 3,5,3′-triiodo-L-thyronine, T3) are able to bind to integrin αβ3 on cells (4–11). The interaction between thyroid hormone and integrin αβ3 (11) has been demonstrated to promote cancer cell proliferation in various types of cancer cells, including breast cancer (12, 13), lung cancer (10, 14), glioma cells (15, 16), myeloma cells (17), pancreatic cancer (18), and colorectal cancer cells (6, 7, 13, 19). Crosstalk between epidermal growth factor (EGFR) and the integrin has been reported to be involved in regulation of cancer cell proliferation (7, 13). Signal transduction mechanisms mediate the promotion of cancer cell proliferation by thyroid hormone and such mechanisms can be blocked by tetradiodothyroacetic acid (tetrac) (7, 13), a deaminated analog of thyroid hormone.

Tetrac has been shown to compete with thyroid hormone, e.g., L-thyroxine (T4) for the iodothyronine receptor on integrin αβ3. Tetrac inhibits binding of thyroid hormones, thus inhibiting the downstream signal transduction pathways of nongenomically initiated effects of thyroid hormone (4, 7, 19–21). Tetrac also has actions at the receptor that are independent of the functions of thyroid hormone, for example, modulation of angiogenesis by multiple mechanisms and regulation of tumor cell metabolism (22). Its interaction with integrin αβ3 permits tetrac to modify differentially regulated gene expression that is related to cancer cell survival pathways. Tetrac up-regulates expression of pro-apoptotic Bcl-x short form (12), anti-angiogenic thrombospondin 1 (THBS1) and other pro-apoptotic genes (4). In addition, tetrac downregulates transcription of several families of anti-apoptotic genes. A nano-formulation of tetrac, nano-diamino-tetrac (NDAT), has been shown to act primarily at the cell surface and does not enter the nucleus when it does enter the cell.

Recently we have studied the anti-proliferative effects of tetrac, NDAT, and their combinations with other anticancer drugs on colorectal cancer cells (4, 7, 13, 19–21). In combination with resveratrol, NDAT downregulated resveratrol-induced ribonucleotide reductase regulatory subunit M2 (RRM2) gene expression in vivo and potentiated the anticancer effect of the stilbene (20). In addition, tetrac enhanced nuclear abundance of chibby family member 1 (CBY1), a nuclear β-catenin antagonist, which is a protein that may compromise nuclear β-catenin-dependent gene expression and proliferation (6). Gefitinib-induced anti-proliferation in gefitinib-resistant colorectal cancer cells is restored by NDAT; the mechanism involves inhibition of beta-galactoside alpha-2, 6-sialyltransferase 1 (ST6Gal1) activity and PI3K activation (7). These observations indicate that added or enhanced effects are obtained with combinations of tetrac or NDAT and other chemotherapeutic agents.

In the current report, we investigated mechanisms by which tetrac- and NDAT induced anti-proliferation in colorectal cancer cells. In addition, we report studies conducted to define the different gene profiles induced by tetrac and NDAT in colorectal cancer cell lines. Finally, using a novel perfusion bellows cell culture system, we have distinguished the mechanisms by which tetrac or NDAT work on human colorectal cancer cells with different K-RAS status.

MATERIALS AND METHODS

Cell Cultures

Human colorectal cancer cell lines HT-29 (ATCC® HTB-38™) and HCT 116 (ATCC® CCL-247™) were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were maintained in RPMI-1640 medium (Life Technologies Corp. Carlsbad, CA, USA) supplemented with 10% FBS and grown under 5% CO2/95% air at 37°C routinely. Prior to treatments, cells were washed with phosphate buffered saline (PBS) and then serum-free medium was added for starvation for 48 h. Then, the serum-free medium was replaced by 5% stripped FBS containing medium at the initiations of studies.

Pharmacodynamics

Anti-proliferative effects of tetrac and NDAT were defined in a well-established perfusion bellows cell culture system (13, 23). At the outset, 5 × 10^7 cells were seeded in perfusion bellows cell culture system and incubated at 37°C overnight. Then polymer flakes were harvested, trypsinized, and cells were collected and counted. The number of original cells attached to flakes was 0.5 × 10^7 cells/bottle. Cell cultures were refreshed with 1% stripped FBS-containing medium. Tetrac or NDAT was added in a medium bottle to the final concentrations indicated in the Results section. Specific concentration of tetrac and NDAT were chosen according to the physiological concentration of T4 (10−7 M) as described previously (24–26). The samples of cell-bearing flakes were then treated as indicated, and cells were harvested at timeframe indicated, trypsinized, and collected for counting. The cell cultures were refreshed with 10% hormone-stripped FBS containing medium.

Quantitative Real-Time PCR (QPCR)

Total RNA was extracted and genomic DNA was eliminated with the Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare Life Sciences, Buckinghamshire, UK). One microgram of DNase I-treated total RNA was reverse-transcribed with a RevertAid H Minus First Strand cDNA Synthesis Kit (Life Technologies Corp.) into cDNA and used as the template for real-time PCR reactions and analysis. The real-time PCR reactions were performed using QuantiNovaTM SYBR® Green PCR Kit (QIAGEN, Valencia, CA, USA) on a CFX Connect™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). This involved an initial denaturation at 95°C for 5 min, followed by 40 cycles of denaturing at 95°C for 5 s and combined annealing/extension at 60°C for 10 s, as described in the manufacturer’s instructions. The primer sequences were: Homo sapiens integrin, alpha v (ITG αv), forward 5’-TCC GATTCCAAACTGGGAGC-3’ and reverse 5’-AAGGCCACTG AAGATGGAGC-3’ (Accession No.: NM_002210.4); Homo sapiens integrin, beta 3 (ITG β3), forward 5’-CTGGTGTTTTACCACTGATGCCAAG-3’ and reverse 5’-TGGTGGAGG
PIG3 (Accession No.: NM_032989.2); Homo sapiens caspase 2, apoptosis-related cysteine peptidase (CASP2), forward 5′-GCTAGTATCCTCACCCTGTATA-3′ and reverse 5′-CAGACGGCGAGCTTTGTGTA-3′ (Accession No.: NM_032982.3); Homo sapiens v-myc avian myelocytomatosis viral oncogene homolog, (c-Myc), forward 5′-TTCCGGTAGTGGAAACCGAG-3′ and reverse 5′-CAGACGGCGAGCTTTGTGTA-3′ (Accession No.: NM_001204384.1); THBS1 (Accession No.: NM_000212.2); and tumor protein p53 inducible gene 3 (PI3) / tumor protein p53 inducible protein 3 (TP53I3) death (p53) (Accession No.: NM_000546.5); Homo sapiens cyclin-dependent kinase inhibitor IA (p21), forward 5′-CTGCGGATGTCGGTCAGAAAC-3′ and reverse 5′-CTTAGGCGATACAGTCGGC-3′ (Accession No.: BT006719.1); Homo sapiens BCL2-associated agonist of cell death (BAD), forward 5′-CTTTAAGAGGGACCTCCCTGCC-3′ and reverse 5′-AAGTTCGAGTACACCAGGA-3′ (Accession No.: NM_032989.2); Homo sapiens vascular endothelial growth factor A (VEGF-A), forward 5′-TTAGGCCATCTGGACAT GTG-3′ and reverse 5′-GGGTAATCCTTCTGGGATAG-3′ (Accession No.: NM_004881.4); Homo sapiens tumor protein p53 (p53), forward 5′-TGATGATTCTGCCCTCCTT-3′ and reverse 5′-CATCTGGCTGCAATCCAATCCA-3′ (Accession No.: NM_001204384.1); Homo sapiens programmed death ligand 1 (PD-L1) (CD274), forward 5′-GTGGTAAAGACGAGCTCCTCC-3′ and reverse 5′-ACCCTGGA TCGTGAATT-3′ (Accession No. NM_014143.3); Homo sapiens thrombospondin 1, (THBS1), forward 5′-ATCTGGACTCCG TGTAGGT-3′ and reverse 5′-GTCATCGTCCCTTCCGTTGT-3′ (accession no.: BC136470.1); and Homo sapiens 18S ribosomal RNA (18S), forward 5′-GTAACCCGTTGAACCCATT-3′ and reverse 5′-CATCCCAATCGGTAGACG-3′ (Accession No. NR_003286). The relative gene expression normalized to the housekeeping gene Luminol Reagent (Millipore). Images of the western blots were visualized and recorded with an Amersham Imager 600 (GE Healthcare, Chicago, IL, USA). The blots were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
cancer K-RAS-mutant HCT116 cells and K-RAS-wild type HT-29 cells were set in 10 mL Petri dishes and starved with serum-free media for 2 days. Prior to starting each experiment, cells were re-fed with fresh medium. Cells were treated with 1 µg/mL anti-integrin αvβ3 30 min before treatment of either $10^{-7}$ M tetrac or NDAT for 30 min. Total proteins were extracted and Western blot analyses were conducted for pERK1/2 study. Tetrac inhibited activation of ERK1/2, but NDAT increased activated ERK1/2 in HT-29 cells (Figure 1B). On the other hand, tetrac and NDAT inhibited constitutively
activated ERK1/2 in HCT116 cells (Figure 1C). However, this effect was partially removed by anti-integrin αvβ3 antibody pretreatment (Figures 1B,C).

Parallel studies were conducted to define the expression of specific genes controlled by tetrac or NDAT. Colorectal cancer HCT116 cells were set in 6-well trays and starved with serum-free media for 2 days. Prior to starting each experiment, cells were re-fed with fresh medium. Cells were treated with 1 μg/mL anti-integrin αvβ3 for 30 min prior to treatment with $10^{-7}$ M tetrac or NDAT for 24 h. Total RNA was extracted and qPCR was conducted for integrin α (ITG α), integrin β3 (ITG β3), CASP2, CCND1, c-Myc, and THBS1. Results shown in Figure 2 indicate that both tetrac and NDAT inhibited expression of CCND1 and c-Myc, but promoted expression of CASP2 and THBS1. The effect of NDAT was much greater than that of tetrac. However, pretreatment of cells with anti-integrin αvβ3 blocked the effect of tetrac and NDAT (Figure 2). These results suggest that both tetrac and NDAT bind to integrin αvβ3 to induce downstream signals that play an important role in tetrac/NDAT-dependent cellular activities.
Tetrac and NDAT Induce Anti-proliferation in Colorectal Cancer Cells With Different K-RAS Status

Two colorectal cancer cell lines were seeded in the perfusion bellows cell culture system. Different concentrations of tetrac (10⁻⁸, 10⁻⁷, and 10⁻⁶ M) or NDAT (10⁻⁹, 10⁻⁸, and 10⁻⁷ M) were added to medium bottles. Tetrac of various concentrations (10⁻⁸, 10⁻⁷, and 10⁻⁶ M) significantly reduced cell number of K-RAS-wild type HT-29 cells after 4 days of treatment, as did NDAT (10⁻⁸ and 10⁻⁷ M). NDAT (10⁻⁸ M) reduced 37% of cell number after 4 days of treatment, but tetrac (10⁻⁷ M) only reduced 28.4% of cell number compared to untreated control (Figure 3).

After 6 days of treatment, tetrac (10⁻⁸ and 10⁻⁷ M) significantly reduced cell number of K-RAS-mutant HCT116 cells (Figure 4). On the other hand, different concentrations of NDAT (10⁻⁹, 10⁻⁸, and 10⁻⁷ M) inhibited cancer cell proliferation significantly after 2 days of treatment. NDAT (10⁻⁹ M) reduced 52.5% of cell number at day 2, but tetrac (10⁻⁸ M) reduced 11.5% of cell number at day 5 compared to untreated control (Figure 4).

Cells treated with tetrac and NDAT were also prepared for flow cytometry studies. Results shown in Figure 5 indicate that tetrac induced cancer cell arrested in G2/M stage. However, low concentration 10⁻⁸ M NDAT induced G2/M arrest and 10⁻⁷ M NDAT shut down DNA synthesis.

NDAT and Tetrac Modulate Expression of Different Genes in Colorectal Cancer Cells

We observed previously that treatment with tetrac or NDAT results in different gene expression profiles in MDA-MB-231 cells and in medullary thyroid carcinoma cells (24). In order to define the gene transcription profiles induced by tetrac and by NDAT in colorectal cancer cells with different K-RAS status, HT-29 cells and HCT116 cells were treated with 10⁻⁸ and 10⁻⁷ M tetrac or NDAT, respectively for 24 h. RNA was extracted from the harvested cells at the end of treatment for qPCR studies. Treatment with NDAT (10⁻⁸ M) for 24 h increased expression of p53 and p53-responsible genes such as p21, PIG3 (TP53I3), BAD, and CASP2 in HT-29 cells significantly (Figure 5). In addition, NDAT increased expression of THBS1.

Protein TSP1 is an endogenous suppressor of angiogenesis and is invariably suppressed in cancer cells. Although tetrac also increased expression of those genes, the effect was 10-fold less (Figure 5). In contrast, tetrac (10⁻⁸ and 10⁻⁷ M) significantly increased expression of p21, p53, PIG3, BAD, and THBS1 genes in HCT116 cells (Figure 6). However, 10⁻⁸ M tetrac did not significantly inhibit expression of VEGF-A, which plays an important role in HCT116 cells metastasis (Figure 6). On the other hand, NDAT also increased expression of the mentioned genes and significantly decreased expression of VEGF at 10⁻⁸ M.

DISCUSSION

The perfusion bellows cell culture studies we describe here provide useful pharmacodynamic information of the application of new drugs or combinations of various agents in vitro to human cancer cell lines (13). Pharmacodynamic modeling based
Tetrac/NDAT Inhibit Colorectal Cancer Growth

Chin et al.

The pharmacokinetics of a drug permits—in the expected pharmacokinetics of a drug permits—in the understanding of dose-response relationship of antineoplastic agents over a very wide range of concentration in *vitro* and can support translation from *vitro* models to animal models and ultimately human clinical trials.

Via binding to the thyroid hormone receptor on plasma membrane integrin αvβ3 (27, 28), NDAT induces signal transduction and biological activities similar to those of unmodified tetrac (Figures 1, 2), but with desirable effects on cell survival pathway genes that differ from the parent thyroid hormone analog (Figures 2, 5, 6) (5, 24). Studies indicated that NDAT but not tetrac activated ERK1/2 in K-RAS-wild type colorectal cancer HT-29 cells (Figure 1A), which confirms previous results that NDAT activates ERK1/2 in HT-29 cells (24). On the other hand, both tetrac and NDAT inhibited ERK1/2 activation in K-RAS-mutant HCT-116 cells (Figure 1B). Interestingly, NDAT is more sensitive to the inhibitory effect of pretreatment of cells with of anti-integrin αvβ3 (Figure 2). Both tetrac and NDAT induced anti-proliferation in colorectal cancer K-RAS-wild type HT-29 cells and in K-RAS-mutant HCT116 cells (Figures 3, 4). The growth-inhibitory effects of tetrac and NDAT on HCT116 colon cancer cell xenografts are evident in 2–4 d after the onset of treatment (6, 7, 20). The anti-proliferative effect of tetrac and NDAT on cancer cells in the perfusion bellows cell culture system were seen at 3 d after the start of treatment (Figures 3, 4). Pharmacodynamics of anti-proliferative activities in *vitro* of tetrac and NDAT in colorectal cancer cells were compared in the perfusion bellows cell culture system. Results revealed that NDAT had a higher potency than tetrac as an anti-proliferative agent (Figure 3). We have previously shown that the anticancer effects of tetrac and NDAT in colorectal cancer HCT116 cell xenografts are well-established within 3 d after onset of drug administration (6, 7). Although inhibitory effects of tetrac and NDAT in the perfusion bellows cell culture system are limited to suppression of cell proliferation, these results in the perfusion system reproduce findings obtained earlier in the same cells in xenografts. Tetrac-/NDAT-induced anti-tumor effects in xenografts have been shown to involve both primary effects on tumor cell proliferation and anti-angiogenesis effect (6, 7). Results in these sets of studies similarly demonstrate that the anticancer effects of tetrac/NDAT occur first as anticancer cell proliferation.

The inhibition of HT-29 cell growth by NDAT and tetrac was comparable at a higher drug concentration (10<sup>−7</sup> M), but there was increased sensitivity to NDAT at a lower drug concentration of the used agents (Figure 3). In addition to the anti-proliferative effects initiated at the cell surface integrin receptor, tetrac may penetrate into cells to exert low-grade thyromimetic (proliferative) effects in the nucleus of treated colorectal cancer cells. Therefore, the net anti-proliferative effect of tetrac decreases. On the other hand, NDAT does not gain access to the cell nucleus and shows a more robust anti-proliferative effect.

In addition to their anti-proliferative effects on cancer cells, tetrac and NDAT have been shown to enhance anti-cancer growth by other anticancer drugs. Cetuximab (Erbitux<sup>⃝</sup>) inhibits K-RAS wild-type but not K-RAS mutant colorectal cancer cell growth (19). The combination of tetrac and cetuximab significantly reduced cell proliferation compared to cetuximab.
FIGURE 5 | Tetrac and NDAT suppress expression of proliferative and metastasis-related genes in HT-29 cancer cells. HT-29 cells were seeded in 6-well plates and treated with different concentrations of $10^{-8}$ and $10^{-7}$ M tetrac or NDAT for 24 h. Cells were harvested and total RNA was extracted. qPCR experiments were conducted to examine expression of anti-proliferative genes (p21, p53, and PI33), apoptotic genes (BAD and CASP2) and metastasis-related genes (THBS1). N = 6. (Data are expressed as mean. ± SD; *p < 0.05, **p < 0.01, ***p < 0.001, compared with untreated control).

alone in K-RAS mutant HCT 116 cells, but not in K-RAS wild type COLO 205 cells (19). NDAT also rescued the anti-proliferative effect of cetuximab in both colorectal cancer cell lines (19). These results suggest that tetrac and NDAT may be used in the clinic in the future to treat K-RAS-mutant colorectal cancer patients. However, present studies indicated that NDAT was much more effective than tetrac (Figures 5, 6). Furthermore, NDAT reversed K-RAS mutant-dependent cetuximab resistance. In addition, xenograft weights in NDAT-treated alone animals are not significantly decreased compared to those in untreated control [result not shown (6, 7)]. Therefore, NDAT alone or combination with low dosage of cetuximab may be a new chemotherapeutic approach in the future.

Studies have shown that tetrac affects only XIAP gene expression (12) in breast cancer cells. On the other hand, NDAT downregulates expression of apoptosis inhibitors XIAP, myeloid cell leukemia sequence 1 (MCL1), and apoptosis-promoting genes such as CASP2 and BCL2L14 (12). Expression of the angiogenesis inhibitor thrombospondin 1 (THBS1) gene is increased by both unmodified tetrac and NDAT, as is the expression of CBY1, a nuclear inhibitor of catenin activity (12). The majority of differentially regulated K-RAS-oncogene family members and the epidermal growth factor receptor gene are downregulated by NDAT, but not by tetrac (12). β-Catenin belongs to a class of catenins that have been shown to play roles in cell-cell adhesion. It also has transcription functions. Various cancers such as those of the colorectum,
FIGURE 6 | Tetrac and NDAT suppress expression of proliferative and metastasis-related genes in HCT116 cancer cells. HCT116 cells were seeded in 6-well plates and treated with different concentrations of $10^{-8}$ and $10^{-7}$ M tetrac or NDAT for 24 h. Cells were harvested and total RNA was extracted. Studies of qPCR were conducted to examine expression of anti-proliferative genes (p21, p53, and PIG3), apoptotic gene (BAD), and metastasis-related genes (VEGF-A and THBS1). N = 6. (Data are expressed as mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001, compared with untreated control).

breast, and ovary have been shown to contain mutant and overexpressed β-catenin genes. CBY1, an inhibitor of nuclear functions of β-catenin, is upregulated by NDAT. Like β-catenins, integrin αvβ3 participates in cellular adhesion complexes. NDAT downregulates expression of the gene for integrin β3 monomer. Since integrin αvβ3 has been shown to involve metastasis and migration, this may be a desirable action of NDAT at αvβ3 in cancer cells.

NDAT also downregulates expression of the genes for α-catenins, CTNNA1 and CTNNA2 (8). Mutation of CTNNA2 is associated with tumor invasiveness and thus inhibition of transcription of the gene is desirable. The nonmutated gene product of CTNNA1 can function as a tumor invasion suppressor, but mutation is associated with gastrointestinal tract and other cancers.

Thyroid hormone induces expression of MMP-2 and MMP-9 in myeloma cells and colorectal cancer cells (7). This action is inhibited by tetrac and NDAT; this implies that αvβ3 can be involved in the contribution of matrix metalloproteinases to cancer-relevant angiogenesis and to tumor invasiveness. Tetrac and NDAT were able to inhibit constitutive expression of VEGF-A (Figure 6). Tetrac and NDAT also increased transcription of thrombospondin 1 (THBS1, TSP1), which suppresses angiogenesis.

In summary, tetrac and NDAT via integrin αvβ3 regulate thyroid hormone-dependence of various independent cancer cell activities. NDAT is much more potent than tetrac and has a
broader range of transcriptional actions in cancer cells that may be clinically desirable.

**AUTHOR CONTRIBUTIONS**

Y-TC, Z-RH, C-LC, KW, H-YL, and JW-P: conceptualizing research idea. H-CC, YH, P-YS, Y-CY, and KW: developing methodologies. P-YS, Y-CY, KW, Y-JS, Y-RC, AWN, and H-YT: performing experiments. JZP, SI, Y-JS, Y-RC, AWN, and H-YT: collecting and analyzing data. JZP and SI: Interpreting data. H-YL and PJD: writing manuscript. SAM, PJD, and JZP: proofreading and editing.

**REFERENCES**

1. Davis PJ, Sudha T, Lin HY, Mousa SA. Thyroid hormone, hormone analogs, and angiogenesis. *Compr Physiol*. (2015) 6:353–62. doi: 10.1002/cphy.c150011

2. Lin HY, Hsieh MT, Cheng GY, Lai HY, Chin YT, Shih YJ, et al. Mechanisms of action of nonpeptide hormones on resveratrol-induced antiproliferation of cancer cells. *Ann NY Acad Sci*. (2017) 1403:92–100. doi: 10.1111/nyas.13423

3. Chin YT, Wei PL, Ho Y, Nana AW, Changou CA, Chen YR, et al. Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells. *Endocr Relat Cancer*. (2018) 25:533–45. doi: 10.1530/ERC-17-0376

4. Lin HY, Chin YT, Yang YC, Lai HY, Wang-Peng J, Liu LF, et al. Thyroid hormone, cancer, and apoptosis. *Compr Physiol*. (2016) 6:1221–37. doi: 10.1002/cphy.c150035

5. Lee YS, Chin YT, Shih YJ, Nana AW, Chen YR, Wu HC, et al. Thyroid hormone promotes beta-catenin activation and cell proliferation in colorectal cancer. *Horm Cancer*. (2018) 9:156–65. doi: 10.1007/s12672-018-0324-y

6. Nana AW, Chin YT, Lin CY, Ho Y, Bennett JA, Shih YJ, et al. Tetrac downregulates beta-catenin and HMG2A to promote the effect of resveratrol in colon cancer. *Endocr Relat Cancer*. (2018) 25:279–93. doi: 10.1530/ERC-17-0450

7. Chang TC, Chin YT, Nana AW, Wang SH, Liao YM, Chen YR, et al. Enhancement by nano-diamino-tetrac of antiproliferative action of gefitinib on colorectal cancer cells: mediation by EGFR sialylation and PI3K activation. *Horm Cancer*. (2018) 9:420–32. doi: 10.1007/s12672-018-0341-x

8. Davis PJ, Glinsky GV, Lin HY, Leith JT, Herbergs A, Tang HY, et al. Cancer cell gene expression modulated from plasma membrane integrin alphavbeta3 by thyroid hormone and nanoparticles tetrac. *Front Endocrinol*. (2014) 5:240. doi: 10.3389/fendo.2014.00240

9. Incerpi S, Hsieh MT, Lin HY, Cheng GY, De Vito P, Fiore AM, et al. Thyroid hormone inhibition in L6 myoblasts of IGF-I-mediated glucose uptake and proliferation: new roles for integrin alphavbeta3. *Am J Physiol Cell Physiol*. (2014) 307:C150–61. doi: 10.1152/ajpcell.00308.2013

10. Meng R, Tang HY, Westfall J, London D, Cao JH, Mousa SA, et al. Crosstalk between integrin alphavbeta3 and estrogen receptor-alpha is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. *PLoS ONE*. (2011) 6:e27547. doi: 10.1371/journal.pone.0027547

11. Davis PJ, Mousa SA, Lin HY. Tetraiodothyroacetic acid (tetrac), integrin alphavbeta3 and disabling of immune checkpoint defense. *Future Med Chem*. (2018) 10:1637–9. doi: 10.4155/fmc-2018-0123

12. Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB, et al. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). *Cell Cycle*. (2009) 8:3562–70. doi: 10.4161/cc.8.21.9963

13. Lin HY, Landersdorfer CR, London D, Meng R, Lim CU, Lin C, et al. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. *PLoS Comput Biol*. (2011) 7:e1001073. doi: 10.1371/journal.pcbi.1001073

14. Mousa SA, Talcin M, Bharali DJ, Meng R, Tang HY, Lin HY, et al. Tetraiodothyroacetic acid and its nanomorphine inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts. *Lung Cancer*. (2012) 76:369–45. doi: 10.1016/j.lungcan.2011.10.003

15. Herbergs AH, Lin HY, Davis FB, Davis PJ, Leith JT. Radiosensitization and production of DNA double-strand breaks in U87MG brain tumor cells induced by tetraiodothyroacetic acid (tetrac). *Cell Cycle*. (2011) 10:352–7. doi: 10.4161/cc.10.14.6461

16. Lin HY, Glinsky GV, Mousa SA, Davis PJ. Thyroid hormone and anti-apoptosis in tumor cells. *Oncotarget*. (2015) 6:14735–45. doi: 10.18632/oncotarget.4023

17. Cohen K, Flint N, Shalev S, Erez D, Baharal T, Davis PJ, et al. Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via alphavbeta3 integrin in myeloma cells. *Oncotarget*. (2014) 5:6312–22. doi: 10.18632/oncotarget.2205

18. Yalcin M, Lin HY, Sudha T, Bharali DJ, Meng R, Tang HY, et al. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. *Horm Cancer*. (2013) 4:176–85. doi: 10.1007/s12672-013-0137-y

19. Lee YS, Chin YT, Yang YSH, Wei PL, Wu HC, Shih A, et al. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status. *Steroids*. (2016) 111:63–70. doi: 10.1016/j.steroids.2016.03.006

20. Nana AW, Wu SY, Yang YS, Chin YT, Cheng TM, Ho Y, et al. Nano-diamino-tetrac (NDAT) enhances resveratrol-induced antiproliferation by action on the RRM2 pathway in colorectal cancers. *Horm Cancer*. (2018) 9:349–60. doi: 10.1007/s12672-018-0334-9

21. Lin SJ, Chin YT, Ho Y, Chou SY, Sh Yang YC, Nana AW, et al. Nano-diamino-tetrac (NDAT) inhibits PD-L1 expression which is essential for the anti-proliferation action of resveratrol in breast cancer cells in vitro. *Oncotarget*. (2014) 5:12891–907. doi: 10.18632/ott.2018.06.058

22. Davis PJ, Lin HY, Sudha T, Yalcin M, Tang HY, Herbergs A, et al. Nanotetra targets integrin alphavbeta3 on tumor cells to disorder cell defense pathways and block angiogenesis. *Onco Target Ther*. (2017) 10:1619–24. doi: 10.2147/OTT.T76793

23. Chen YT, Hsieh MT, Yang SH, Tsai PW, Wang SH, Wang CC, et al. Anti-proliferative and gene expression actions of resveratrol in breast cancer cells in vitro. *Oncotarget*. (2014) 5:12891–907. doi: 10.18632/oncotarget.2632

24. Lin HY, Chin YT, Nana AW, Shih YJ, Lai HY, Tang HY, et al. Actions of L-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells. *Steroids*. (2016) 114:59–67. doi: 10.1016/j.steroids.2016.03.006

25. Lin HY, Su YF, Hsieh MT, Lin S, Meng R, London D, et al. Nuclear monomeric integrin alphav in cancer cells is a coactivator regulated

**FUNDING**

This work was supported in part by grant from Wan-Fan Hospital Collaborating Program (JW-P, 98TMU-WFH-02-1), by Chair Professor Research Fund, to KW, by Chair Professor Research Fund to JW-P, by the TMU Research Center of Cancer Translational Medicine from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, general grant of Ministry of Science and Technology Taiwan (H-YL, MOST 107-2314-B-038-017) and a gift from PJD to Albany College of Pharmacy and Health Sciences.
by thyroid hormone. *FASEB J.* (2013) 27:3209–16. doi: 10.1096/fj.12-227132

26. Lin HY, Shih A, Davis FB, Davis PJ. Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells. *Biochem J.* (1999) 338 (Pt. 2):427–32. doi: 10.1042/bj3380427

27. Sudha T, Bharali DJ, Yalcin M, Darwish NH, Debreli Coskun M, Keating KA, et al. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. *Int J Nanomed.* (2017) 12:1305–15. doi: 10.2147/IJN.S123742

28. Sudha T, Bharali DJ, Yalcin M, Darwish NH, Coskun MD, Keating KA, et al. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac. *Nanomedicine.* (2017) 12:195–205. doi: 10.2217/nnm-2016-0315

**Conflict of Interest Statement:** Co-authors SAM and PJD are co-inventors of NDAT and stockholders in a company that is commercializing the agent.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2019 Chin, He, Chen, Chu, Ho, Su, Yang, Tang, Mousa, Davis and Whang-Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*